The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3
Anjali Sibley(Center for Disease Analysis), Samir M. Fakhry(Abu Dhabi University), Pauls Aldiņš(Pauls Stradiņš Clinical University Hospital), A. Almessabi(Abu Dhabi Health Services), Sameer Alawadhi(Dubai Health Authority), Chris Estes(Center for Disease Analysis), Faisal Abaalkhail(Alfaisal University), Mihály Makara(Unified Szent István and Szent László Hospital), Abdulrahman Aljumah, A. Abourached(Ministry of Public Health), Seyed Moayed Alavian(Baqiyatallah University of Medical Sciences), Ainrisq Rifai(Mafraq Hospital), Altaf Alam(Shaikh Zayed Hospital), Kwang‐Hyub Han(Yonsei University), N. Andrea(Abu Dhabi Health Services), Huda Al Quraishi(Dubai Health Authority), Samsuridjal Djauzi(University of Indonesia), L. Al‐Dabal(Dubai Health Authority), Abdullah M. Assiri(King Khalid University), Ehsan Hassan(Dubai Health Authority), Wasim Jafri(Aga Khan University), Y. Al Serkal(Al Ain Hospital), Abdul Rahman Bizri, Agha Wajdan Baqir(Nishtar Medical College and Hospital), Maha T Barakat(Abu Dhabi Health Services), Adel Alqutub(King Fahd Medical City), Sarah Blach(Center for Disease Analysis), Moon Seok Choi(Samsung Medical Center), T. Diab(Al Ain Hospital), Zaigham Abbas(Ziauddin University), K. Al Jaberi(Abu Dhabi Health Services), Khalid Alswat(King Saud University), Adrian Goldiș(Victor Babeș University of Medicine and Pharmacy Timișoara), Abdullah Alghamdi(King Fahd Medical City), Hamad I. Al‐Ashgar(King Faisal Specialist Hospital & Research Centre), Asad Chaudhry(GIFT University), Faleh Z. Al-Faleh, R. Salupere(Tartu University Hospital), Mohammed A. Babatin(King Fahd Medical City), Ottar M. Bergmann(National University Hospital of Iceland), Salem Khoury(University of Balamand), Raafat F. Alhakeem(Ministry of Health), Farida Al Hosani(Abu Dhabi Health Services), Maryam Al Khatry(American University of Ras Al Khaimah), I. Altraif(King Saud bin Abdulaziz University for Health Sciences), Ahmed Ms Abdou(Dubai Health Authority), F. Al Braiki(Abu Dhabi Health Services), Mariam Al Mulla(Abu Dhabi Health Services), Laurentius A. Lesmana(University of Indonesia)
Cited by 77
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
World Gastroenterology Organisation Global Guidelines
|Journal of Clinical Gastroenterology|2014|521
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
|The Lancet. Gastroenterology & hepatology|2023|399
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
|Hepatology International|2020|295
Global burden of metabolic diseases, 1990–2021
|Metabolism|2024|294